| William Frederick Waters, PHD | |
|
9001 Summa Ave, Baton Rouge, LA 70809-3726 | |
| (225) 761-5200 | |
| (225) 761-5512 |
| Full Name | William Frederick Waters |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 55 Years |
| Location | 9001 Summa Ave, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053346908 | NPI | - | NPPES |
| 1530760 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 347 (Louisiana) | Secondary |
| 103TC0700X | Psychologist - Clinical | 347 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo Panels, which tap into Sermo's active online community of more than 110,000 practicing MDs, generate fresh, actionable MD feedback.
MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.
Surgical patients are more likely to experience a postoperative infection if they have low health literacy, which is a limited capacity to understand and act on health information, according to results of a new study presented at the American College of Surgeons 2020 Quality and Safety Conference VIRTUAL.
A new laser technique has demonstrated that it can measure the interactions between proteins tangled in a cell's membrane and a variety of other biological molecules. These extremely difficult measurements can aid the process of drug discovery.
Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.
› Verified 8 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo Panels, which tap into Sermo's active online community of more than 110,000 practicing MDs, generate fresh, actionable MD feedback.
MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.
Surgical patients are more likely to experience a postoperative infection if they have low health literacy, which is a limited capacity to understand and act on health information, according to results of a new study presented at the American College of Surgeons 2020 Quality and Safety Conference VIRTUAL.
A new laser technique has demonstrated that it can measure the interactions between proteins tangled in a cell's membrane and a variety of other biological molecules. These extremely difficult measurements can aid the process of drug discovery.
Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Frederick Waters, PHD 10310 The Grove Blvd, Baton Rouge, LA 70836-6455 Ph: (225) 761-5200 | William Frederick Waters, PHD 9001 Summa Ave, Baton Rouge, LA 70809-3726 Ph: (225) 761-5200 |
News Archive
Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo Panels, which tap into Sermo's active online community of more than 110,000 practicing MDs, generate fresh, actionable MD feedback.
MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.
Surgical patients are more likely to experience a postoperative infection if they have low health literacy, which is a limited capacity to understand and act on health information, according to results of a new study presented at the American College of Surgeons 2020 Quality and Safety Conference VIRTUAL.
A new laser technique has demonstrated that it can measure the interactions between proteins tangled in a cell's membrane and a variety of other biological molecules. These extremely difficult measurements can aid the process of drug discovery.
Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.
› Verified 8 days ago